# Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

> **NCT05696782** · PHASE2 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 28 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer Stage III
- Unresectable Non-Small Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer, Stage II

## Interventions

- **DRUG:** Durvalumab
- **OTHER:** the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)
- **DIAGNOSTIC_TEST:** COPD Assessment Test (CAT)
- **DIAGNOSTIC_TEST:** Modified Medical Research Council (mMRC) dyspnea scale

## Key facts

- **NCT ID:** NCT05696782
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2027-02
- **Final completion:** 2027-04
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696782, "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05696782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*